Cidara partners its antiviral conjugate platform for seasonal and pandemic influenza with Janssen, which also gets option rights to an AVC candidate for respiratory syncytial virus.

New comprehensive study of drug coupons offered by manufacturers, pharmacies, pharmacy benefit managers and state programs, and who uses the discounts, takes a more holistic look at patient assistance programs than previous work. Researchers raise concerns that the offsets don’t seem well targeted at people with high financial or clinical need. 

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Health technology assessment body NICE believes that Calquence may be better tolerated and cause fewer side effects than existing treatments.